Potiga (ezogabine) receives FDA approval

Potiga (ezogabine) receives FDA approval

Valeant Pharmaceuticals International Inc. (Meda's partner for ezogabine
- known as retigabine outside of the U.S.) has received approval from
the U.S. Food and Drug Administration (FDA) for Potiga (ezogabine).
Potiga is approved for adjunctive treatment for adults with
partial-onset seizures. It is the first approved potassium channel
opener for this indication.

“We are glad to see Potiga approved in the U.S. and we hope that this
novel treatment can be beneficial to patients”, said Anders Lönner, CEO
Meda AB.

This FDA approval triggers a milestone payment to Meda of 6 MUSD. Meda
is also entitled to receive royalties in the U.S. of 7% on net sales and
other milestone payments related to future development of the product.
GlaxoSmithKline is responsible for the global commercialization.

Trobalt (retigabine) was approved in Europe on 28 March 2011 and the
launch by GlaxoSmithKline has already begun in Germany, the UK,
Switzerland and Denmark. Meda will receive a royalty of between 6 - 8%
in Europe.

For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: 46
709-458 878